Position：Chair of Medical Oncology
Department：Medical Oncology
Medical School：Zhejiang University School of Medicine, China
Academic Rank：Chief Physician
Dr. Yuan focuses on the treatment and clinical research of gastrointestinal (GI) malignancies, mainly on the development of new drugs and biologic/targeted-oriented agents in treatment. This includes translational and immune research of GI cancers with great experiences in the early phase clinical trial (phase I, II, III) designing, protocol development, and conduction. In addition, she also has a lot of experience in the personalized and comprehensive treatment of hereditary colorectal cancer.
Southern California Society of Colon and Rectal Surgeons Award, 1997
Zhejiang Scientific and Technological Progress Award, First Prize, 2002
State Scientific and Technological Progress Award, Second Prize, 2005
Zhejiang Scientific and Technological Progress Award, Second Prize, 2015
China Cancer Young Scientist Award, 2016
Science and Technology Award of Chinese Anti-Cancer Association, Third Prize, 2017
Yunnan Scientific and Technological Progress Award, First Prize, 2017
Science and Technology Progress Award of Yunnan Province, 2018
The Health high-level innovative talents of Zhejiang Province, 2021
Member of the American Society of Clinical Oncology (ASCO)
Board Member of the Chinese Society of Clinical Oncology (CSCO)
Youth Board Member, the Chinese Anti-Cancer Association
Vice Chairman, Committee of Colorectal cancer, Chinese Society of Clinical Oncology (CSCO)
Vice Chairman, Committee of Familial Genetic Cancer, Chinese Anti-Cancer Association
Vice Chairman, Committee of Oncology, Zhejiang Medical Association
Chairman, Committee of Familial Genetic Cancer, Zhejiang Anti-Cancer Association
1988-1995 Bachelor and Master of Oncology, Zhejiang University School of Medicine, Hangzhou, China
1995-1998 Ph.D. in Oncology, Zhejiang University School of Medicine, Hangzhou, China
1999-2001 Postdoc in Human Genetics, Luebeck Medical University, Luebeck, Germany
Dr. Yuan Ying is currently mainly engaged in the research of personalized drug therapy for colorectal cancer and the pathogenesis of hereditary colorectal cancer, including clinical research, translational research and basic research. She is currently undertaking three projects related to colorectal cancer funded by the National Natural Science Foundation of China, National Key R&D Program, and Key Discipline Construction Project of Chinese Medicine in Zhejiang Province. She has made great achievements in the field of individualized comprehensive diagnosis and treatment of colorectal cancer. She also has extensive experience in clinical research. So far she has led 5 multi-center clinical trials and participated in more than 30 international and domestic clinical studies.
In addition, she won more than 10 domestic and foreign awards, including the second prize of State Scientific and Technological Progress Award, the first prize of Zhejiang's and Yunnan's Scientific and Technological Progress Award, the Chinese Young Cancer Oncologist Award and the Southern California Association of Colorectal Surgeons Award. Dr. Yuan has published more than 150 articles, including 80 SCI papers.
Ye C, Lu Y, Yuan Z, Mi M, Qi L, Yuan Y, Weng S. Ferroptosis regulator FANCD2 is associated with immune infiltration and predicts worse prognosis in lung adenocarcinoma. Front Genet. 2022 Oct 4;13:922914. doi: 10.3389/fgene.2022.922914.
Hong X, Hu Y, Yuan Z, Fang Z, Zhang X, Yuan Y, Guo C. Oxidatively Damaged Nucleic Acid: Linking Diabetes and Cancer. Antioxid Redox Signal. 2022 Dec;37(16-18):1153-1167. doi: 10.1089/ars.2022.0096.
Mei WJ, Mi M, Qian J, Xiao N, Yuan Y, Ding PR. Clinicopathological characteristics of high microsatellite instability/mismatch repair-deficient colorectal cancer: A narrative review. Front Immunol. 2022 Dec 23;13:1019582. doi: 10.3389/fimmu.2022.1019582.
Fu X, Ying J, Yang L, Fang W, Han W, Hu H, Zhang S, Yuan Y. Dual targeted therapy with pyrotinib and trastuzumab for HER2-positive advanced colorectal cancer: A phase 2 trial. Cancer Sci. 2022 Nov 16. doi: 10.1111/cas.15660.
Aisa A, Weng S, Li X, Zhang D, Yuan Y. Immune checkpoint inhibitors combined with HER-2 targeted therapy in HER-2 positive gastroesophageal cancer. Crit Rev Oncol Hematol. 2022 Dec;180:103864. doi: 10.1016/j.critrevonc.2022.103864.
Ye C, Deng Y, Sun W, Yuan Y. Editorial: Recent advances of drug resistance research in colorectal cancer therapy. Front Oncol. 2022 Nov 22;12:1059223. doi: 10.3389/fonc.2022.1059223.
Mi M, Ye C, Yuan Y. Neoadjuvant PD-1 blockade: a promising nonoperative strategy for mismatch repair-deficient, locally advanced rectal cancer. Signal Transduct Target Ther. 2022 Oct 10;7(1):361. doi: 10.1038/s41392-022-01216-3.
Guo J, Shen Y, Hu S, Rui T, Liu J, Yuan Y. Neobavaisoflavone inhibits antitumor immunosuppression via myeloid-derived suppressor cells. Int Immunopharmacol. 2022 Oct;111:109103. doi: 10.1016/j.intimp.2022.109103.
Zhu N, Zhao Y, Mi M, Lu Y, Tan Y, Fang X, Weng S, Yuan Y. REV1: A novel biomarker and potential therapeutic target for various cancers. Front Genet. 2022 Sep 29;13:997970. doi: 10.3389/fgene.2022.997970.
Zhu N, Hu H, Yuan Y. Circulating tumor DNA analysis: potential to revise adjuvant therapy for stage II colorectal cancer. Signal Transduct Target Ther. 2022 Sep 5;7(1):308. doi: 10.1038/s41392-022-01164-y.
Chen J, Zhang D, Yuan Y. Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma. Clin Exp Med. 2022 Aug 26. doi: 10.1007/s10238-022-00873-6.
Aisa A, Tan Y, Li X, Zhang D, Shi Y, Yuan Y. Comprehensive Analysis of the Brain-Expressed X-Link Protein Family in Glioblastoma Multiforme. Front Oncol. 2022 Jul 4;12:911942. doi: 10.3389/fonc.2022.911942.
Weng S, Zhang D, Yang M, Wang L, Yuan Y. Vemurafenib effectively controlled Chemotherapy-refractory Intrahepatic Cholangiocarcinoma with BRAF V600E Mutation: a case report and literature review. Z Gastroenterol. 2022 Dec;60(12):1787-1791. English. doi: 10.1055/a-1826-2814. Epub 2022 May 18.
Liu Y, Xiao Q, He J, Hu H, Du J, Zhu Y, Chen J, Liu Z, Wang J, Sun L, Xu D, Li J, Liao X, Wang J, Cai Y, Cai C, Jin Z, Wang L, Yuan Y, Ding K. Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy. BMC Med. 2022 May 6;20(1):155. doi: 10.1186/s12916-022-02357-6. PMID: 35513832.
Yuan Z, Weng S, Ye C, Hu H, Zhang S, Yuan Y. CSCO guidelines for colorectal cancer version 2022: Updates and discussions. Chin J Cancer Res. 2022 Apr 30;34(2):67-70. doi: 10.21147/j.issn.1000-9604.2022.
Chen T, Yuan Y. Editorial: Familial Cancer in China: From Detection to Screening and Management. Front Oncol. 2022 Apr 29;12:916814. doi: 10.3389/fonc.2022.916814.
Cheng X, Zhang F, Gong J, Li Y, Zhou D, Wang J, Vong EG, Yuan Y, Lai M, Zhang D. Identification of potential functional variants and genes at 18q21.1 associated with the carcinogenesis of colorectal cancer. PLoS Genet. 2022 Feb 2;18(2):e1010050. doi: 10.1371/journal.pgen.1010050.
Lu YE, Ye CY, Yuan Y. Phenotypic characteristics and T cell receptor properties in melanoma: deciphering the correlation at single-cell resolution. Signal Transduct Target Ther. 2022 Jan 4;7(1):5. doi: 10.1038/s41392-021-00864-1.
Zhong X, Hu XY, Zhao P, Wang YB, Fang XF, Shen JY, Shen H, Yuan Y. The efficacy of low-power cumulative high-intensity focused ultrasound treatment for recurrent desmoid tumor. Cancer Med. 2022 May;11(10):2079-2084. doi: 10.1002/cam4.4573. Epub 2022 Mar 11.
Qi LN, Ye CY, Zhang D, Bai R, Zheng S, Hu WX, Yuan Y. The Effects of Differentially-Expressed Homeobox Family Genes on the Prognosis and HOXC6 on Immune Microenvironment Orchestration in Colorectal Cancer. Front Immunol. 2021 Dec 7;12:781221. doi: 10.3389/fimmu.2021.781221. eCollection 2021.
Zhao J, Shen H, Hu XY, Wang YB, Yuan Y. The efficacy of a new high-intensity focused ultrasound therapy for metastatic pancreatic cancer. Int J Hyperthermia. 2021;38(1):288-295. doi: 10.1080/02656736.2021.1876252.
Guo-Li Gu, Zhi Zhang, Yu-Hui Zhang, Peng-Fei Yu, Zhi-Wei Dong, Hai-Rui Yang, Ying Yuan. Detection and analysis of common pathogenic germline mutations in Peutz-Jeghers syndrome. World J Gastroenterol. 2021 Oct 21;27(39):6631-6646.
Rui Bai, Dehao Wu, Zhong Shi, Wangxiong Hu, Juan Li, Yuanyuan Chen, Weiting Ge, Ying Yuan, Shu Zheng. Pan-cancer analyses demonstrate that ANKRD6 is associated with a poor prognosis and correlates with M2 macrophage infiltration in colon cancer. Chin J Cancer Res. 2021 Feb 28;33(1):93-102.
Yiqiu Hu, Zhihao Fang, Jiayi Mu, Yanqin Huang, Shu Zheng, Ying Yuan, Cheng Guo. Quantitative Analysis of Methylated Adenosine Modifications Revealed Increased Levels of N-6-Methyladenosine (m(6)A) and N-6,2 '-O-Dimethyladenosine (m(6)Am) in Serum From Colorectal Cancer and Gastric Cancer Patients. Front Cell Dev Biol. 2021 Jul 26;9:694673.
Lina Qi, Jiani Chen, Biting Zhou, Kailun Xu, Kailai Wang, Zhihao Fang, Yingkuan Shao, Ying Yuan, Shu Zheng, Wangxiong Hu. HomeoboxC6 promotes metastasis by orchestrating the DKK1/Wnt/beta-catenin axis in right-sided colon cancer. Cell Death Dis. 2021 Apr 1;12(4):337.
Ying-Xin Zhao, Xiao-Ye Hu, Xian Zhong, Hong Shen, Ying Yuan. High-intensity focused ultrasound treatment as an alternative regimen for myxofibrosarcoma. Dermatol Ther. 2021 Mar;34(2):e14816.
Haochen Zhang, Xuefeng Fang, Dan Li, Mengyuan Yang, Linzhen Yu, Yuwei Ding, Hong Shen, Ying Yuan. Hyperprogressive disease in patients receiving immune checkpoint inhibitors. Curr Probl Cancer. 2021 Jun;45(3):100688.
Mengyuan Yang, Lila Zhu, Lizhen Zhu, Dong Xu, Ying Yuan. Role of a Rare Variant in APC Gene Promoter 1B Region in Classic Familial Adenomatous Polyposis. Digestion. 2021;102(4):527-533.
Yuwei Ding, Shanshan Weng, Xinyu Li, Ding Zhang, Adilai Aisa, Ying Yuan. General treatment for metastatic colorectal cancer: From KEYNOTE 177 study. Transl Oncol.2021 Aug;14(8):101122.
Yi Zou, Long Wu, Yubin Yang, Zonghui Ding, Jiaming Huang, Peng Li, Chunpeng Zhu, Ying Yuan. Serum lipid levels correlate to the progression of gastric cancer with neuroendocrine immunophenotypes: A multicenter retrospective study. Transl Oncol. 2021 Jan;14(1):100925.
Mengyuan Yang, Yingxin Zhao, Yuwei Ding, Juan Wang, Yinuo Tan, Dong Xu, Ying Yuan. A truncated protein product of the germline variant of the DUOX2 gene leads to adenomatous polyposis. Cancer Biol Med. 2021 Feb 15;18(1):215-226.
Ning Zhu, Xuefeng Fang, Dan Li, Mengyuan Yang, Lizhen Zhu, Liping Zhong, Shanshan Weng, Juan Wang, Ying Yuan. Identification and prognostic analysis of the cetuximab resistance-related gene REV1 in RAS wild-type metastatic colorectal cancer. Am J Cancer Res. 2021 Jun 15;11(6):2769-2781.
Mengyuan Yang, Dan Li, Wu Jiang, Lizhen Zhu, Haixing Ju, Yan Sun, Yuqiang Shan, Chunkang Yang, Jian Dong, Lin Wang, Baoping Wu, Meng Qiu, Xianli Yin, Xicheng Wang, Bin Xiong, Wei Yan, Tao Liu, Chenglin Liu, Xinru Mao, Kefeng Ding, Suzhan Zhang, Shu Zheng, Dong Xu, Peirong Ding, Ying Yuan. Development and external validation of a novel nomogram for screening Chinese Lynch syndrome: based on a multicenter, population study. Ther Adv Med Oncol. 2021 Jun 14;13:17588359211023290.
Huang YQ, Mu JY, Qi LN, Ge WT, Fang XF, Song YM, Yuan Y, Zheng S. Diverse fragment lengths dismiss size selection for serum cell-free DNA: a comparative study of serum and plasma samples. Clin Chem Lab Med, 2020 Mar 28;58(9):1451-1459. doi: 10.1515/cclm-2020-0078.Print 2020 Aug 27.
Yang MY, Zhong X, Yuan Y. Does Baking Soda Function as a Magic Bullet for Patients With Cancer? A Mini Review. Integr Cancer Ther, Jan-Dec 2020;19:1534735420922579. doi: 10.1177/1534735420922579.
Chen Q, Hu YQ, Fang ZH, Ye MF, Li JQ, Zhang SZ, Yuan Y, Guo C. Elevated Levels of Oxidative Nucleic Acid Modification Markers in Urine From Gastric Cancer Patients: Quantitative Analysis by Ultra Performance Liquid Chromatography-Tandem Mass Spectrometry. Frontiers Chemistry, 2020 Dec 17;8:606495. doi: 10.3389/ fchem.2020.606495. eCollection 2020.
Chen J, Zhang H, Zhu L, Zhao Y, Ding Y, Yuan Y. Tislelizumab for the treatment of classical Hodgkin's lymphoma. Drugs Today (Barc). 2020 Dec;56(12):781-785. doi: 10.1358/dot.2020.56.12.3233362. PMID: 33332484.
Ding Y, Wang J, Zhu N, Xu D, Ding K, Yuan Y. Fruquintinib effectively controlled the advanced small bowel adenocarcinoma progressed after multiple lines of palliative treatment: a case report and literature review. Cancer Biol Ther. 2020 Dec 1;21(12):1105-1108. doi: 10.1080/15384047.2020.1836549. Epub 2020 Nov 5. PMID: 33151122; PMCID: PMC7722796.
Hu H, Liu X, Cai W, Wu D, Xu J, Yuan Y. A Retrospective Exploration of Targeted Maintenance Therapy in Advanced Colorectal Cancer: Based on the Background of Chinese Patient Assistance Program. Front Oncol. 2020 Apr 23;10:522. doi: 10.3389/fonc.2020.00522. PMID: 32391263; PMCID: PMC7190810.
Weng S, Zhu N, Li D, Chen Y, Tan Y, Chen J, Yuan Y. Clinical Characteristics, Treatment, and Prognostic Factors of Patients With Primary Extramammary Paget's Disease (EMPD): A Retrospective Analysis of 44 Patients From a Single Center and an Analysis of Data From the Surveillance, Epidemiology, and End Results (SEER) Database. Front Oncol. 2020 Aug 25;10:1114. doi: 10.3389/fonc.2020.01114. PMID: 32983958; PMCID: PMC7477308.
Weng S, Yuan Y, Wang X, Chen G, Wang Y, Sheng W, Li X, Zhou A, Zhang Z, Li G, Cai S, Xu R, Li J, Zhang S. Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019. Chin J Cancer Res. 2020 Jun;32(3):403-407. doi: 10.21147/j.issn.1000-9604.2020.03.11. PMID: 32694904; PMCID: PMC7369177.
Guo Z, Yang Z, Li D, Tang J, Xu J, Shen H, Yuan Y. Colorectal cancer with invasive micropapillary components (IMPCs) shows high lymph node metastasis and a poor prognosis: A retrospective clinical study. Medicine (Baltimore). 2020 May 22;99(21):e20238. doi: 10.1097/MD.0000000000020238. PMID: 32481300; PMCID: PMC7249862.
Wang J, Nishiyama A, Matsuyama M, Wang Z, Yuan Y. The (pro)renin receptor: a novel biomarker and potential therapeutic target for various cancers. Cell Commun Signal. 2020 Mar 6;18(1):39. doi: 10.1186/s12964-020-0531-3. PMID: 32143717; PMCID: PMC7060546.
Cheng Y, Fang XF, Hu HG, Wang J, Sun LF, Yuan Y. Successful treatment of metastatic colorectal cancer with synchronous BRAF V600E mutation and dMMR with BGB-A317. Immunotherapy. 2020 Mar;12(4):229-234. doi: 10.2217/imt-2019-0148. Epub 2020 Mar 16. PMID: 32172642.
Li D, Weng SS, Zhong CH, Xu D, Yuan Y. Risk of second primary cancers among survivors of breast cancer. Front Oncol. 2020 Jan 13;9:1426. doi: 10.3389/ fonc.2019.01426. eCollection 2019.
Tan YN, Hu YT, Xiao Q, Tang Y, Chen HY, He JJ, Chen LB, Jiang K, Wang ZH, Yuan Y, Ding KF. Silencing of brain-expressed X-linked 2 (BEX2) promotes colorectal cancer metastasis through the Hedgehog signaling pathway. Int J Biol Sci. 2020 Jan 1;16(2):228-238. doi: 10.7150/ijbs.38431. eCollection 2020.
Lu W, Fu DL, Kong XX, Huang ZH, Hwang M, Zhu YS, Chen LB, Jiang K, Li XL, Wu YH, Li J, Yuan Y, Ding KF. FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms. Cancer Medcine 2020 Feb;9(4):1419-1429. doi: 10.1002/cam4.2786. Epub 2020 Jan 1.
Zhu N, Dong CX, Weng SS, Yuan Y. A Patient of Advanced NSCLC with a New EGFR Exon 19 Insertion Mutation and its Response to EGFR-TKIs. J Coll Physicians Surg Pak. 2019 Dec;29(12):S126-S128. doi: 10.29271/jcpsp.2019.12.S126.
Zhu N, Weng SS, Wang J, Chen JQ, Yu LZ, Fang XF, Yuan Y. Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. J Cancer Res Clin Oncol. 2019 Dec;145(12):3021-3036. doi: 10.1007/s00432-019-03044-5. Epub 2019 Oct 15.
Zhong CH, Fang XF, Zhu LZ, Li D, Tang JL, Yuan Y. Report of two cases and a systematic review of breast cancer with gastrointestinal metastasis. Turk J Gastroenterol. 2019 Nov;30(11):997-1000. doi: 10.5152/tjg.2019.18649.
Zhong CH, Yu JK, Li D, Jiang K, Tang Y, Yang MY, Shen H, Fang XF, Ding KF, Zheng S, Yuan Y. Zyxin as a potential cancer prognostic marker promotes the proliferation and metastasis of colorectal cancer cells. J Cell Physiol. 2019 Jan 29. doi: 10.1002/jcp.28236.
Yu LZ, Wang LH, Tan YN, Hu HG, Shen L, Zheng S, Ding KF, Zhang SZ, Yuan Y. Accuracy of Magnetic Resonance Imaging in Staging Rectal Cancer with Multidisciplinary Team: A Single-Center Experience. J Cancer. 2019 Oct 21;10(26):6594-6598. doi: 10.7150/jca.32685. eCollection 2019.
Yang MY, Zhu LZ, Xu D, Weng SS, Fang XF, Dong CX, Hu HG, Yuan Y. How should we correctly interpret biallelic germline truncating variant of MLH3 in hereditary colorectal cancer? Genet Med. 2019 Nov;21(11): 2650-2651. doi: 10.1038/ s41436-019-0529-7. Epub 2019 May 2.
Yuan Y, Wang XC, Chen G, et al. Updates in Version 2019 of the CSCO Guidelines for Colorectal Cancer from Version 2018. Chin J Cancer Res. 2019 Jun;31(3):423-425. doi: 10.21147/j.issn.1000-9604.2019.03.03.
Tang XJ, Fang XF, Zhu LZ, Wei OC, Bai XL, Liang TB, Yuan Y. Metastatic mixed acinar-neuroendocrine carcinoma of pancreas treated with multidisciplinary team: A case report and brief review of the literature. Journal of Digestive Disease, 2019 Jun;20(6):318-322. doi: 10.1111/1751-2980.12752. Epub 2019 May 7
Tan YN, Fu DL, Li D, Kong XX, Jiang K, Chen L, Yuan Y. Ding KF. Predictors and risk factors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Population Based Analysis. Frontiers in Oncology, 2019 Jun 13;9:497. doi: 10.3389/fonc.2019.00497. eCollection 2019.
Cheng Y, Weng SS, Yu LZ, Zhu N, Yang MY, Yuan Y. The role of hyperthermia in the multidisciplinary treatment of malignant tumors. Integrative Cancer Therapies, 2019 Jan-Dec;18:1534735419876345. doi: 10.1177/1534735419876345
Li D, Zhong CH, Cheng Y, Zhu N, Tan YN, Zhu LZ, Xu D, Yuan Y. A Competing Nomogram to Predict Survival Outcomes in Invasive Micropapillary Breast Cancer. Journal of Cancer. J of Cancer 2019 Nov 1;10(27):6801-6812. doi: 10.7150/jca.27955. eCollection 2019
CSCO colorectal group. Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018. Chin J Cancer Res. 2019 Feb;31(1):117-134. doi: 10.21147
Clinical implications of familial colorectal cancer. Funding Source: Sino-German Center for Research Promotion.
The effect and mechanism of combined treatment of a RAS-mimetic small molecule rigosertib and cetuximab in RAS-mutant colorectal cancer. Funding Source: National Natural Science Foundation of China.
System integration, performance evaluation and clinical path study on early diagnosis and treatment of big data in malignant tumors. Funding Source: National Key Research and Development Program.
Study on molecular mechanism of honokiol induced RIP1 independent programmed necrosis in breast cancer cells. Funding Source: Zhejiang Province Chinese Medicine (Integrated Chinese and Western Medicine) Key Subject Construction Project.
National Colorectal Cancer Cohort. Funding Source: National Key Research and Development Program.
Research on early warning, intervention and individualized comprehensive diagnosis and treatment of common gastrointestinal malignant tumors based on proteomics. Funding Source: National Key Research and Development Program.
Study on the subtype function of Treg cells in the microenvironment of breast cancer. Funding Source: National Natural Science Foundation of China.
Clinical Trials:
RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer. NCT05785325
Serplulimab+Regorafenib+Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases. NCT05894837
A Real-world Study of Trifluridine/Tipiracil Containing Regimen for the Treatment of Patients With mCRC (REFLECT Study). NCT06195111
Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab.
Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer. NCT06134765
SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer. NCT05160896
Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer. NCT04194359
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RASmutant Metastatic Colorectal Cancer. NCT05171660
Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer. NCT04733963
Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status. NCT05409417
A Single-arm Phase II Study of Short-course Radiotherapy Followed by AK104 Combined With XELOX Neoadjuvant Therapy Followed by Delayed Surgery for Locally Advanced Rectal Cancer.
RALOX as Second Line Treatment for Advanced Malignant Biliary System Tumor (RALOXBTC). NCT05148143
Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Patients Meeting Chinese Lynch Syndrome Criteria. NCT03046849
MFOLXOX6 Versus FOLFIRI for Colorectal Patients Recurrence After Oxaplatin Based Adjuvant Chemotherapy. NCT05362617
Real-world Retrospective Data Analysis of Adjuvant Therapy for Patients With Stage II-III Colon Cancer After Radical Surgery. NCT03958435
Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Colorectal Cancer. NCT03047226
Multicenter Study on the Pathogenic Germline Gene Variants of Colorectal Polyposis in China. NCT04961125
Establishment and Clinical Validation of New Technologies for Accurate Screening of Colorectal Cancer Based on Multi-omics. NCT04913233
Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal Cancer. NCT04819516
QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer (BEVTOR). NCT04527068
88 Jiefang Road,Shangcheng District Hangzhou,China, 310009
1511 Jianghong Road,Binjiang District Hangzhou,China, 310014
300 Yuanju Road, Shangcheng DIstrict, Hangzhou
456 Qidi Road, Xiaoshan District, Hangzhou, China
1 Xihu Avenue, Shangcheng District, Hangzhou
Zijingang Campus of Zhejiang University, 866 Yuhangtang Road, Xihu District, Hangzhou
Please call +86-571-8971 3988 (8am-5pm, Monday through Friday)
Make an appointment online
The Second Affiliated Hospital
Zhejiang University School of Medicine
88 Jiefang Road, Hangzhou, China
+86-571-8731 5108
iao_sahzu@zju.edu.cn
The Needs of Patients and Customers Come First.
The Second Affiliated Hospital Zhejiang University School of Medicine
All Rights Reserved.
